XML 53 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Strategic and License Agreements - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Oct. 24, 2014
Sep. 30, 2017
Oct. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Feb. 27, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Inventory write-down       $ 0 $ 2,232 $ 0  
Payments to acquire global rights to preclinical development program     $ 1,500        
Endo Ventures manufacturing and supply agreement              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Cash received for reimbursements   $ 1,500          
Net receivables   4,700          
Raw materials   2,300          
Notes payable   7,000          
Contract termination fee   2,500          
Contract termination costs       $ 500      
Brabant Pharma Limited [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Aggregate amount of contingent liabilities $ 95,000            
Regulatory Milestones [Member] | Brabant Pharma Limited [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Aggregate amount of contingent liabilities 50,000            
Sales Milestones [Member] | Brabant Pharma Limited [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Aggregate amount of contingent liabilities $ 45,000            
Sumavel DosePro [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Inventory write-down   2,200          
Impairment of prepaid royalties   $ 2,000          
Subsequent Event [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Contingent development milestone payment             $ 10,000